Correction of postkidney transplant anemia reduces progression of allograft nephropathy

Journal of the American Society of Nephrology

Volumn 23, Issue 2, 2012, Pages 360-368

  Choukroun, Gabriel ^a   Kamar, Nassim ^b   Dussol, Bertrand ^c   Etienne, Isabelle ^d   Cassuto Viguier, Elisabeth ^e   Toupance, Olivier ^f   Glowacki, François ^g   Moulin, Bruno ^h   Lebranchu, Yvon ⁱ   Touchard, Guy ^j   Jaureguy, Maïté ^a   Pallet, Nicolas ^k   Le Meur, Yannick ^l   Rostaing, Lionel ^b   Martinez, Frank ^k  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b Nephrology Dialysis and Organ Transplantation Department   (France)

^c Nephrology Dialysis and Transplantation Department   (France)

^d Nephrology and Transplantation Department   (France)

^e Nephrology and Transplantation Department   (France)

^f Nephrology and Transplantation Department   (France)

^g Nephrology and Transplantation Department   (France)

^h Nephrology and Transplantation Department   (France)

ⁱ Nephrology and Transplantation Department   (France)

^j Nephrology and Transplantation Department   (France)

^k HÔPITAL NECKER ENFANTS MALADES   (France)

^l Nephrology and Transplantation Department   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; CONTROLLED STUDY; CREATININE CLEARANCE; DEATH; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

EID: 84856827831     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2011060546     Document Type: Article

References (32)

1. Vanrenterghem Y, Ponticelli C, Morales JM, Abramowicz D, Baboolal K, Eklund B, Kliem V, Legendre C, Morais Sarmento ALM, Vincenti F: Prevalence andmanagement of anemia in renal transplant recipients: A European survey. Am J Transplant 3: 835-845, 2003 (Pubitemid 36827905)
2. Winkelmayer WC, Kewalramani R, Rutstein M, Gabardi S, Vonvisger T, Chandraker A: Pharmacoepidemiology of anemia in kidney transplant recipients. J AmSoc Nephrol 15: 1347-1352, 2004 (Pubitemid 38526017)
3. Choukroun G, Deray G, Glotz D, Lebranchu Y, Dussol B, Bourbigot B, Lefrançois N, Cassuto-Viguier E, Toupance O,Hacen C, Lang P,Mazouz H, Martinez F: Incidence and management of anemia in renal transplantation: an observational-French study. Nephrol Ther 4: 575-583, 2008
4. Molnar MZ, Mucsi I, Macdougall IC, Marsh JE, Yaqoob M, Main J, Courtney AE, Fogarty D, Mikhail A, Choukroun G, Short CD, Covic A, Goldsmith DJ: Prevalence and management of anaemia in renal transplant recipients: Data from ten European centres. Nephron Clin Pract 117: c127-c134, 2011
5. Kawada N, Moriyama T, Ichimaru N, Imamura R, Matsui I, Takabatake Y, Nagasawa Y, Isaka Y, Kojima Y, Kokado Y, Rakugi H, Imai E, Takahara S: Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients. Clin Exp Nephrol 13: 355-360, 2009
6. Winkelmayer WC, Chandraker A, Alan Brookhart M, Kramar R, Sunder- Plassmann G: A prospective study of anaemia and long-term outcomes in kidney transplant recipients. Nephrol Dial Transplant 21: 3559-3566, 2006 (Pubitemid 44817110)
7. Molnar MZ, Czira M, Ambrus C, Szeifert L, Szentkiralyi A, Beko G, Rosivall L, Remport A, Novak M, Mucsi I: Anemia is associated with mortality in kidney-transplanted patients-a prospective cohort study. Am J Transplant 7: 818-824, 2007 (Pubitemid 46481205)
8. Heinze G, Kainz A, Hörl WH, Oberbauer R: Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: Cohort study. BMJ 339: b4018, 2009
9. Solid CA, Foley RN, Gill JS, Gilbertson DT, Collins AJ: Epoetin use and Kidney Disease Outcomes Quality Initiative hemoglobin targets in patients returning to dialysis with failed renal transplants. Kidney Int 71: 425-430, 2007
10. Kamar N, Rostaing L:Negative impact of one-year anemia on long-term patient and graft survival in kidney transplant patients receiving calcineurin inhibitors and mycophenolate mofetil. Transplantation 85: 1120-1124, 2008 (Pubitemid 351590189)
11. Chhabra D, Grafals M, Skaro AI, Parker M, Gallon L: Impact of anemia after renal transplantation on patient and graft survival and on rate of acute rejection. Clin J Am Soc Nephrol 3: 1168-1174, 2008
12. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S,Wolfson M, Reddan D CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098, 2006 (Pubitemid 44749317)
13. Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084, 2006 (Pubitemid 44749316)
14. Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJV, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl JMed 361: 2019-2032, 2009
15. Locatelli F, Aljama P, Canaud B, Covic A, De Francisco A, Macdougall IC,Wiecek A, Vanholder R Anaemia Working Group of European Renal Best Practice (ERBP): Target haemoglobin to aim for with erythropoiesis- stimulating agents: A position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 25: 2846-2850, 2010
16. Linde T, Ekberg H, Forslund T, Furuland H, Holdaas H, Nyberg G, Tydén G, Wahlberg J, Danielson BG: The use of pretransplant erythropoietin to normalize hemoglobin levels has no deleterious effects on renal transplantation outcome. Transplantation 71: 79-82, 2001 (Pubitemid 32105782)
17. Lietz K, Lao M, Paczek L, Górski A, Gaciong Z: The impact of pretransplant erythropoietin therapy on late outcomes of renal transplantation. Ann Transplant 8: 17-24, 2003
18. Martinez F, Kamar N, Pallet N, Lang P, Durrbach A, Lebranchu Y, Adem A, Barbier S, Cassuto-Viguier E, Glowaki F, Le Meur Y, Rostaing L, Legendre C, Hermine O, Choukroun G NeoPDGF Study Investigators: High dose epoetin beta in the first weeks following renal transplantation and delayed graft function: Results of the Neo-PDGF Study. Am J Transplant 10: 1695-1700, 2010
19. Ware JE Jr, Sherbourne CD: The MOS 36-itemshort-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30: 473-483, 1992
20. Laupacis A, Pus N, Muirhead N, Wong C, Ferguson B, Keown P: Disease- specific questionnaire for patients with a renal transplant. Nephron 64: 226-231, 1993 (Pubitemid 23153050)
21. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R ERA-EDTA ERBP Advisory Board: Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 24: 348-354, 2009
22. Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 363: 1146-1155, 2010
23. Szczech LA, Barnhart HX, Inrig JK, Reddan DN, Sapp S, Califf RM, Patel UD, Singh AK: Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes. Kidney Int 74: 791-798, 2008
24. Singh AK: Does correction of anemia slow the progression of chronic kidney disease? Nat Clin Pract Nephrol 3: 638-639, 2007
25. Zeisberg M, Neilson EG:Mechanisms of tubulointerstitial fibrosis.J Am Soc Nephrol 21: 1819-1834, 2010
26. Deicher R, Hörl WH: Anaemia as a risk factor for the progression of chronic kidney disease. Curr Opin Nephrol Hypertens 12: 139-143, 2003 (Pubitemid 36288313)
27. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB: Beyond anemia: the clinical impact of the physiologic effects of erythropoietin. Semin Dial 21: 447-454, 2008
28. Keithi-Reddy SR, Addabbo F, Patel TV,Mittal BV, Goligorsky MS, Singh AK: Association of anemia and erythropoiesis stimulating agents with inflammatory biomarkers in chronic kidney disease. Kidney Int 74: 782-790, 2008
29. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, Lee BH, Park RW, Park KM, Kim YJ, Kim IS, Kwon TH, Kim YL: Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: Role of inhibiting TGF-b-induced epithelial-to-mesenchymal transition. J Am Soc Nephrol 18: 1497-1507, 2007
30. Robertson H, Ali S, McDonnell BJ, Burt AD, Kirby JA: Chronic renal allograft dysfunction: The role of T cell-mediated tubular epithelial to mesenchymal cell transition. J Am Soc Nephrol 15: 390-397, 2004 (Pubitemid 38140779)
31. Jevnikar AM, Mannon RB: Late kidney allograft loss: What we know about it, and what we can do about it. Clin J Am Soc Nephrol 3[Suppl 2]: S56-S67, 2008
32. Strutz F: Pathogenesis of tubulointerstitial fibrosis in chronic allograft dysfunction. Clin Transplant 23: 26-32, 2009